Catalog Products » GIP hFc Chimera, Human
Manual
Manual
COAs

GIP hFc Chimera, Human

The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition in non-diabetic individuals.
$340.00
Z05353-100

Ask us a question
Product Introduction
Species Human
Protein Construction
GIP (Glu22-Gln93)
Accession # P09681		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 34.9 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

GIP HFc Chimera, Human

Immobilized GIP hFc Chimera, Human, hFc Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-GIP Antibody, hFc Tag with the EC50 of 58.2ng/ml determined by ELISA. »

GIP HFc Chimera, Human

The purity of GIP hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »

GIP HFc Chimera, Human

GIP hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition in non-diabetic individuals.
Synonyms GIP; Incretin
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.